Kornimate/medical-research-clean huggingface dataset:
japanese registry of rivaroxaban effectiveness & safety for the prevention of recurrence in patients with deep vein thrombosis and pulmonary embolism

Conditions: Deep Vein Thrombosis; Pulmonary Embolism

Summary: to clarify the effectiveness and safety of the direct factor xa inhibitor rivaroxaban in domestic clinical use for patients with deep vein thrombosis and pulmonary embolism

research design: multicenter collaboration, prospective, non-interventional, observational research research outline: registration period: dec 2016 (after ethics committee approval) to may 2018 (1 year and 6 months) investigation period: dec 2016 (after ethics committee approval) to nov 2019 (at least 1 year and 6 months) target number of participants: 1,000 participants estimated number of participating institutions: 150 medical institutions research secretariat: mebix, inc. research procedure: * perform patient registration within 3 weeks of first prescription * also record when the drug was discontinued for any reason, such as an event or bleeding etc, between the time of first prescription and registration * track progress as much as possible until the end of the study period, regardless of continuation or discontinuation of study drug administration, and also in cases where there is manifestation of efficacy or safety events * track progress of all cases as much as possible until the end of the study period, regardless of continuation, discontinuation or termination of study drug administration. patients transferred to the hospital are managed in the same way. registration method: register case information in the web registration system (edc) after obtaining written consent from the research participant him/herself or the legal guardian for all cases compliant with the registration criteria and not in conflict with the exclusion criteria. administer rivaroxaban in compliance with the approved dosage in the separate attached document. furthermore, when the usage or dose are adjusted at the discretion of the research doctor, record the dose adjustment and reason. edc will be used for case data entry. \[edc; items to be entered into the case registration screen\] 1. registration date 2. facility name 3. case registration number 4. patient identification code (appropriate number within the facility) 5. gender 6. birthdate 7. rivaroxaban commencement date 8. age at first prescription (automatic calculation display) 9. date of obtaining written consent 10. other

Eligibility criteria:
inclusion criteria: 1. symptomatic or asymptomatic venous thromboembolism prescribed rivaroxaban exclusion criteria: 1. contraindication to rivaroxaban 2. chronic thromboembolic pulmonary hypertension (however, it is possible to register if there is coexisting acute pulmonary embolism or deep vein thrombosis) 3. active bleeding 4. patients determined to be inappropriate for the study by the attending doctor

Keywords: deep vein thrombosis pulmonary embolism
study to evaluate the efficacy of ruxolitinib 1.5% cream in adult subjects with discoid lupus erythematosus

Conditions: Discoid Lupus Erythematosus

Summary: this study is a single-blind, intraindividual study to evaluate the efficacy of ruxolitinib 1.5 % cream in adult subjects with discoid lupus erythematosus.

this study is being conducted to evaluate the efficacy, safety and tolerability of ruxolitinib 1.5 % cream in adult subjects with discoid lupus erythematosus. approximately 20 subjects with discoid lupus erythematosus will apply ruxolitinib 1.5% cream, twice daily on active lesions identified at day 1 and any new lesions that appear, for 24 weeks.

Eligibility criteria:
inclusion criteria: * male or female subject 18 years of age or older at the time of consent. * confirmed dle diagnosis. * subject has moderate to severe dle, as defined by an overall cla iga score of 3 (moderate) or 4 (severe) at screening and day 1. * female subject of childbearing potential must have a negative urine pregnancy test at screening and negative urine pregnancy test at day 1. * subject has no known history of latent or active tuberculosis (tb) infection. * subject is willing to participate and is capable of giving informed consent. note: consent must be obtained prior to any study-related procedures. * subjects must be willing to comply with all study procedures and must be available for the duration of the study. exclusion criteria: * female subject who is breastfeeding, pregnant, or who is planning to become pregnant during the study. * subject has a history of skin disease or presence of skin condition that would interfere with the study assessments. * subject has unstable or fluctuating use of nicotine-containing products within 4 weeks prior to screening. * subject is known to have immune deficiency or is immunocompromised. * subject is ≥ 50 years old and has a history of heart attack, other clinically significant heart problems, stroke, or blood clots. * subject has a known history of chronic infectious disease (e.g., hepatitis b, hepatitis c, or human immunodeficiency virus \[hiv\]). * subject is known to have hepatitis b or hepatitis c viral infection. * subject has used any topical medicated treatment that could affect dle within 2 weeks prior to day 1, including, but not limited to, topical corticosteroids, retinoids, calcineurin inhibitors, antimicrobials, and medical devices. * subject has received any marketed or investigational biological agent within 12 weeks or 5 half lives (whichever is longer) prior to day 1, including but not limited to ustekinumab and rituximab. * subject is currently receiving a nonbiological investigational product or device or has received one within 4 weeks prior to day 1. * subject has a known or suspected allergy to ruxolitinib. * subject has used ruxolitinib cream (opzeluratm). * subject has used jak inhibitors for conditions other than dle or other forms of lupus within 4 weeks prior to day 1. * subject has a known history of clinically significant drug or alcohol abuse in the last year prior to day 1.

Keywords: discoid lupus erythematosus opzelura ruxolitinib cream
questionnaire for obstetricians and anesthesiologist

Conditions: Uterine Bleeding; Atony, Uterine; Cesarean Section Complications

Summary: the research was planned as a face-to-face survey evaluation. the questionnaire will be applied to obstetricians and anesthesiologists working in public and private hospitals. the universe of the research will be selected by simple random sampling method, and the total number of people who will participate is planned to be 200, approximately 100 from each of the two branches. our survey consists of 5 parts structurally. demographic data, rate of cesarean section and postpartum hemorrhage, uterotonic agent preferences in low/high risk cesarean section surgeries, the preference for second-line uterotonic agents, and the dose preferences of uterotonic agents.


Eligibility criteria:
inclusion criteria: obstetricians and anesthesiologists who want to participate in the survey exclusion criteria: the ones who do not want to participate -
effect of combined remote ischemic preconditioning and postconditioning on acute pulmonary injury in patients undergoing valvular heart surgery

Conditions: Heart Valve Diseases

Summary: pulmonary dysfunction after cardiac surgery with cpb remains to be a problem complicating the postoperative course of the patients. the investigators hypothesized that ripccom, combined intervention of remote ischemic preconditioning and remote ischemic postconditioning, would confer beneficial influence on inflammatory response and resultant postoperative pulmonary dysfunction after cpb in patients undergoing complex valvular heart surgery who are at increased risk of postoperative pulmonary dysfunction.the aim of this study was to evaluate the lung-protective effect of combined remote ischemic pre- and post-conditioning in patients undergoing complex valvular heart surgery.


Eligibility criteria:
inclusion criteria: * patients undergoing valvular heart surgery. * age: 20\~80. exclusion criteria: * emergency operation. * patients with peripheral vascular disease. * patients with a known history or clinical evidence of chronic obstructive pulmonary disease. * patients with hepatic or renal dysfunction * patients with acute myocardial infarction within 1 week before surgery
efficacy of preemptive volume loading to prevent arterial hypotension during induction of general anesthesia

Conditions: Anesthesia

Summary: induction of general anesthesia induces frequently arterial hypotension. the short term goal of this study is to evaluate if preemptive volume loading prevents such complication.

this is a randomized, prospective study which will include a total of 200 patients who are scheduled to undergo elective surgery. the research participants will be randomly assigned to * a control group that will receive a low preemptive volume loading (50 ml of gelatin), * a protocol group that will receive a high preemptive volume loading (500 ml of gelatin). volume loading is preceded by the measurement of stroke volume and cardiac output before and after a passive leg elevation test and followed by a standardized anesthetic protocol.

Eligibility criteria:
inclusion criteria: * adult patients undergoing elective surgery. exclusion criteria: * difficult peripheral venous access * allergy to gelatin * symptomatic cardiac disease, rhythm trouble, pace-maker, aortic valvular disease, aortic disease * morbid obesity, low bmi, * hypovolemia, * raynaud syndrome or scleroderma, * contra-indication to propofol, remifentanil or to the use of bispectral index, * hematocrit \< 20%.

Keywords: propofol anesthesia, induction hypotension cardiac output
effect of coduse balance training and step square exercises on risk of fall in multiple sclerosis

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: to investigate the effect of coduse balance training and step square exercises on the risk of falls in multiple sclerosis. background: risk of fall \& balance disabilities are considered serious problems in multiple sclerosis which results in loss of balance \& physical inactivity. .........hypotheses: this study hypothesized that: coduse balance training and step square exercises will have a significant effect on the risk of falling in multiple sclerosis research question: is there an effect of coduse balance training and step square exercises on risk of fall in multiple sclerosis?

fifty-two patients with multiple sclerosis will participate in this study. the patients will randomly be divided into two equal groups; the control group which received the conventional selected exercise program and the study group received the same exercise training program in addition to coduse balance training and step square exercises, three times per week for four weeks. the evaluation will done pre and post interventions included: biodex balance system (risk falling), short physical performance battery (sppb) \& morse fall scale.

Eligibility criteria:
inclusion criteria: * fifty-two remitting-relapsing multiple sclerosis rrms patients, * age will range as (20:40) years old * illness duration not more than 10 years, * with no relapses over the past three months, * body mass index (25:35) exclusion criteria: * difficulty to communicate or to understand program instructions * any other neurological deficits or orthopedic abnormalities, * secondary musculoskeletal complication * peripheral vestibulopathy, hepatic, renal, hemopoeitic, thyroid and cardiovascular diseases, cognitive dysfunction, * hearing deficits, epilepsy or eeg abnormalities

Keywords: coduse balance step square exercises risk of fall multiple sclerosis
prognostic model of hypertension

Conditions: Hypertension

Summary: the aim of this study was to establish a registration and monitoring system for hypertension in xinjiang from 2020 to 2030 to obtain real information about patient basic information, patient characteristics, diagnostic test patterns, treatment options, and hospitalization outcomes (including mortality). treatment complications, hospitalization costs, and end-of-life events (death, major adverse cardiac events, mild adverse cardiovascular events) in patients with hypertension in xinjiang; and scientific prevention strategies aimed at effectively preventing the onset of hypertension; guidelines in clinical practice recommend, analyze and develop effective treatment strategies to optimize management and outcomes for patients with hypertension; and create cost-effective assessment systems.

the aim of the study is to establish a platform for monitoring, clinical research and translational medicine in xinjiang, which aims to provide a basis for future quality improvement and research, and to promote efforts to improve the prognosis of patients with hypertension, and to translate research into improved care for patients, thereby reducing morbidity and mortality associated with hypertension.

Eligibility criteria:
inclusion criteria: * a patient diagnosed with primary hypertension who was admitted to the first affiliated hospital of xinjiang medical university exclusion criteria: * patients with secondary hypertension, patients with liver and kidney dysfunction, * patients with mental disorders, and patients who are unwilling to participate in this trial
trans-foraminal lumbar epidural injection of dexmedetomidine against magnesium sulfate when combined with dexamethasone in uni-lateral lower limb radicular pain. multi-centeric comparative study

Conditions: Chronic Pain

Summary: transforaminal injection of chronic radicular lower limb injection by either dexmedetomdine or magnesuim sulfate


Eligibility criteria:
inclusion criteria: * age group. 25-75ys old * both sex. * lumber disc protrusion at one or two segments on mri. * chronic lumbar radiculer pain for more than 6 weeks refractory to * medical treatment for at least 4 weeks. . * positve leg rising test at 30-70 degrees. exclusion criteria: * diabetic candidates ( type ior ii). * patient refusal. * mri with disc sequestration. * neurological examination revealed foot drop, neuropathic ulcers * myelopathic or scoliotic patients, . * coagulopathic patients ( cirrhotic patients, on anti-coagulation )
bioactive glass granules in filling of bone defects

Conditions: Bone Tumors

Summary: this is a randomized clinical trial that will be carried out to examine the use of bioactive glass granules (s53p4) as bone graft substitute in filling small and large bone defects as compared with autogenous and allogeneic bone grafting, respectively.

this a single center randomized trial. the hypothesis of the study is that the selected synthetic bone graft (bioactive glass granules, s53p4, vivoxid ltd, turku, finland) is as good as traditional autogenous or allogeneic bone grating in filling of non-traumatic bone defects. a total of 48 patients (stratified into two groups) will be included. the underlying bone disease will include common bening and semi-malign bone tumors (such as enchondroma and giant cell tumors) as well as tumor-like conditions (such as fibrous dysplasia, fibrous cortical defect, solitary bone cysts, aneurysmatic bone cyst). group i (n=24) will include patients with small benign bone lesions amenable to evacuation and autogenous bone grafting as standard of care. the patients will be randomized to autogenous bone grafting or bioactive glass granule filling. the follow-up examinations up to 52 weeks will include plain x-rays at 4, 26, and 52 weeks as well as mri ad 4 and 52 weeks. group ii (n=24) will include patients with a large bone defect. as the selection criteria, large defects have been defined to be defects which need allogeneic bone grafting. the patients will be randomized to allogeneic bone grafting or bioactive glass granule filling. the patients will be followed up to 52 weeks. the follow-up examinations will include x-rays at 4, 26 and 52 weeks as well as pet/ct imaging and mri at 4 weeks and 52 weeks.

Eligibility criteria:
inclusion criteria: * benign bone tumor or tumor-like condition * age 18 years or more * signed informed consent exclusion criteria: * a history of malignancy * a medication affecting bone metabolism * any device (such as pace maker) as contraindication for mri imaging * gravidity

Keywords: bone tumors bioactive glass autogenous bone grafting allogeneic bone grafting pet imaging
stereotactic body radiation therapy for breast cancer

Conditions: Breast Cancer

Summary: this is a prospective, single institution, phase i-ii study of stereotactic body radiotherapy (sbrt) for unresected breast cancer. twenty-four patients with advanced breast cancer who are not candidates for surgery (metastatic disease, unresectable, medically inoperable) or decline surgery will be enrolled in a prospective study using sbrt (4 fractions of radiation therapy over 12-15 days) as the primary treatment modality.


Eligibility criteria:
inclusion criteria: histologically confirmed diagnosis of invasive breast carcinoma of non-lobular histology. unifocal tumour previously assessed by a breast surgeon and medical oncologist, with no surgery being recommended at time of enrollment. primary breast and axillary surgery not recommended/performed due to any of the following: * distant metastatic disease * unresectable t4 disease and/or * medically inoperable and/or * patient declined breast surgery stages t1-t4, n1-n2, m0-m1 disease ability to attend radiation planning and therapy, able to attend for follow-up care able to provide written informed consent. exclusion criteria: received chemotherapy within 3 weeks prior to breast sbrt. (concurrent endocrine therapy is permitted) multifocal or multicentric tumours. ipsilateral supraclavicular or infraclavicular nodal disease \>= 1cm size that is at the level of or superior to the brachial plexus unable to meet the brachial plexus dose constraints despite compromising coverage of target volumes - as per the discretion of the treating physician treatment target volume estimated to occupy \> 50% of the ipsilateral whole breast volume. locally recurrent breast cancer, with previous radiotherapy to the breast, or previous lumpectomy or mastectomy. ipsilateral breast implant. serious non-malignant disease that precludes definitive surgical or radiation treatment (e.g. scleroderma, systemic lupus erythematosus, cardiovascular/pulmonary/renal disease). women who are pregnant or lactating. psychiatric or addictive disorders that preclude obtaining informed consent or adherence to protocol
prevalence of signs and symptoms of tmd in patients wearing double complete dentures, rpd and in dentistry students.

Conditions: Temporomandibular Joint Disorders

Summary: it was proposed in this study to evaluate the prevalence of tmd signs and symptoms in state university of west of parana's dental students with natural dentition, in patients with removable partial dentures and double complete dentures.

the temporomandibular disorder (tmd) has a high prevalence among the population. objectives: to evaluate the prevalence of signs and symptoms of tmd. methodology: 210 randomly selected individuals were evaluated, being divided into three groups with seventy individuals each: group 1 - dental students with natural dentition. group 2 - patients with removable partial dentures. and group 3 - patients with double complete dentures. the questionnaire of the american academy of orofacial pain for triage was employed, then, clinical evaluation was carried out.

Eligibility criteria:
inclusion criteria: - patients wearing double complete denture, patients wearing just removable partial denture and dentate students. exclusion criteria: students in orthodontic treatment or with less than one year after the end of orthodontic treatment were excluded from the research.

Keywords: temporomandibular disorders. dental prosthesis. dental students
the efficacy and safety of meditoxin® in children with cerebral palsy

Conditions: Muscle Spasticity

Summary: the purpose of this study is to evaluate the efficacy and safety of meditoxin® in the treatment of children with cerebral palsy.

the allocated subject is injected meditoxin® 4u/kg body weight(for patients with hemiplegia) or 6u/kg body weight(for patients with diplegia)in the affected gastrocnemius muscle for the treatment of patients who suffer equinus foot deformity with pediatric cerebral palsy due to spasticity. the efficacy and safety are evaluated for 12weeks through 3 follow up visits.

Eligibility criteria:
inclusion criteria: * pediatric patients aged between 2 and 18 years with diagnosis of spastic cerebral palsy * patients with toe-walking due to peroneal muscle spasticity (patients with equinus foot deformity due to spasticity) * patients who voluntarily consent to participate in this study and whose legally acceptable representative has signed the informed consent form (if the patient is able to write, his/her signature should be also obtained). exclusion criteria: * patients who had previously received botulinum toxin within 3 months prior to the study entry * patients with known hypersensitivity to botulinum toxin * patients who requires legs, feet or ankle surgery at present * patients with severe athetoid movement * patients who is participating in other investigational study at present * patients, by the investigator's discretion, who are not suitable for this study.
high-intensity functional training on functional and cognitive performance in people with parkinson's disease.

Conditions: Parkinson Disease

Summary: parkinson's disease (pd) is a progressive and chronic neurodegenerative disease, which presents signs and symptoms both motor (impaired gait, posture, balance, etc.) and cognitive (memory loss, dementia, etc.), all of which are causing disability and assuming a high economic cost. currently, there are already certain authors who have shown how a high-intensity interval training (hiit) protocol produces improvements in cognitive and physical performance in healthy adults6 and in people with multiple sclerosis. however, another modality has been created, such as high-intensity functional training (hift), which can benefit different populations, both healthy and pathological, due to the multimodal nature of the exercises. thanks to multimodality, more aspects such as agility, coordination and precision of movements are worked on compared to unimodal hiit programs that make this relevant work difficult in a person's daily life. the current study aims to demonstrate the effectiveness of a hift training protocol in a specific population, such as people with parkinson's disease.

the hypothesis is that high-intensity functional training (hift), at a motor and cognitive level, provides a greater benefit than conventional programs of strength, balance and cognition, on the functionality and cognitive capacity of people with parkinson's disease. overall objective: - to assess whether the hift training program is associated with significant improvements in functional and cognitive capacity compared to conventional strength, balance and cognition programs in parkinson's patients. secondary objectives: 1. to assess whether the hift program improves the quality of life in patients with pd. 2. to study whether the hift program reduces the degree of dependency of patients with pd. 3. to determine if the hift program improves physical performance in patients with pd 4. to assess whether the hift program reduces the risk of falls in patients with pd. 5. to investigate whether the hift program improves balance in patients with pd. 6. to determine if the hift program improves functional capacity in patients with pd. 7. to study whether the hift program improves cognitive function in patients with pd

Eligibility criteria:
inclusion criteria: * diagnosis of parkinson's disease. * stage i or ii (hoehn - yahr scale). * age between 45 and 80 years. * independent ambulation for 10 consecutive minutes. * regular physical exercise. exclusion criteria: * medical contraindication for physical activity, deafness or limited hearing and very low vision or blind. * vestibular disorders that compromise balance. * psychotic or severe cognitive disorder. * decompensation or changes in medication. * surgical intervention in the last 6 months. * sedentary persons